Physician profile
Dane Stephen Pawlowski
NPI 1104278464
$1,422.69
in general payments reported to CMS, 2019-2025
14 companies · $886 in 2025
The $886 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $537 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,422.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $347.98 | 2024-2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $267.06 | 2025 | |
| Idorsia Pharmaceuticals US INC | $162.50 | 2024-2025 | Quviviq, Quviviq |
| Tactile Systems Technology INC | $143.94 | 2024 | Flexitouch Plus, Entre Plus |
| Intuitive Surgical, INC. | $122.98 | 2024 | |
| Novo Nordisk INC | $110.94 | 2025 | Ozempic, Wegovy, Rybelsus |
| Exact Sciences Corporation | $79.19 | 2025 | The Cologuard Plus Collection Kit |
| Amgen INC. | $56.06 | 2025 | Evenity, Otezla, Repatha |
| Tolmar, INC. | $35.25 | 2025 | Jatenzo |
| Boston Scientific Corporation | $25.28 | 2024 | Wavewriter Alpha Prime 16 |
| E.R. Squibb & Sons, L.L.C. | $23.43 | 2024 | Eliquis |
| Lilly USA, LLC | $19.69 | 2024 | Mounjaro, Zepbound |
| Pfizer INC. | $14.45 | 2024 | |
| Esperion Therapeutics, INC. | $13.94 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dane Pawlowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.